Abstract 221P
Background
First-line immune checkpoint inhibitor (ICI) for cisplatin-ineligible metastatic urothelial carcinoma patients has been approved by FDA and EMA. However, there is still a lack of evidence to directly compare treatment efficacy between ICI and conventional carboplatin-based chemotherapy. Here we conduct a retrospective analysis to compare the survival outcome between ICI and carboplatin treatment.
Methods
The study enrolled 130 metastatic urothelial carcinoma patients who underwent first-line ICI or carboplatin-based chemotherapy at Kaohsiung and Linko Chang Gung Memorial Hospital between May 2001 and Jun 2019. Kaplan-Meier analyses and Cox proportional regression models were used for univariate and multivariate survival analyses.
Results
In total, there were 44 patients (34%) in the ICI group and 86 patients (66%) in the carboplatin group. The median OS was insignificantly different between ICI and carboplatin groups, accounting for 11.1 and 9.5 months (p = 0.46), respectively. The median PFS in ICI and carboplatin groups were 2.5 and 3.7 months, respectively (p = 0.92). On subgroup analysis, OS was significantly worse for ICI treatment in patients with elevated pretreatment white blood cell count (WBC ≥ 10000 × 103/μL) compared with those on carboplatin group (HR 2.41, 95% CI 1.1 – 5.25, p = 0.03).
Conclusions
In this real-world data analysis, we didn’t show significant survival difference in first-line treatment with ICI and carboplatin-based chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract